Active, not recruitingNCT05496972Updated May 22, 2026

Survey Assessment of Patient and Provider Impressions of Telemedicine in Radiation Oncology

An observational study in Hematopoietic and Lymphoid Cell Neoplasm and Malignant Solid Neoplasm, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by M.D. Anderson Cancer Center · Observational

Study type: Observational
Model: Case-only
Time perspective: Cross-sectional
Enrollment: 200
Ages: 18 Years and older
Sex: All

Study summary

To understand more about the opinions of patients and health providers on the use of telemedicine in radiation oncology.

Read the detailed description

Primary Objective:

To characterize patient and provider satisfaction with telemedicine in RO

Secondary Objective:

To provide evidence for or against the use of telemedicine in radiation oncology (RO)
To assess the feasibility of and value added by telemedicine in RO
To describe barriers and facilitators to telemedicine in RO
To identify preferred use cases for telemedicine in RO

Conditions studied

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Browse trials for

Hematologic Neoplasms 1,464

In context

Hematologic Neoplasms

1,464 studies on the registry are indexed under Hematologic Neoplasms; 433 are open to participants now.

This study's planned enrollment of 200 is close to the median of 186 across 326 observational studies indexed under Hematologic Neoplasms.

Browse Hematologic Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years and older
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Probability sample

Study population

MD Anderson Cancer Center

Inclusion criteria

Patients will be eligible if they are aged 18 or older and have undergone at least 1 telemedicine encounter (video visit) with the radiation oncology department at MD Anderson or its affiliates within 2 months from the initiation of the study (and prospectively as the study enrolls). This would include weekly see visits, follow-up visits, or consultations
English speaking
Access to email and internet to complete the survey
Attending physicians in the radiation oncology department who have utilized telemedicine will be contacted to fill out surveys reflecting their experience

Exclusion criteria

Exclusion Criteria:

Protected populations such as adults unable to consent, pregnant women, prisoners, and individuals who are not yet adults will be excluded

Study design

Observational model: Case-only
Time perspective: Cross-sectional
Enrollment: 200 participants (estimated)
Patient registry: No

Groups and cohorts

Telemedicine Visits
Participants are asked to fill out a survey about their experience.
Behavioral: Survey Administration

Interventions

BehavioralSurvey Administration
Patients and providers complete survey over 10 minutes about their perspectives on the use of telemedicine

What researchers measure

Primary outcomes

Patient satisfaction survey with telemedicine in radiation oncology (RO)
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Time frame: through study completion and average of one year.
Provider satisfaction survey with telemedicine in radiation oncology (RO)
Sensitivity analyses will be performed with those rating 9 or higher or less than 9, and for those who "agree" or "strongly agree" with whether they are satisfied with telemedicine compared to those who give other answers.
Time frame: through study completion and average of one year.

Study locations

1 site

MD Anderson Cancer Center
Houston, Texas 77030, United States

References and documents

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT05496972
Lead sponsor: M.D. Anderson Cancer Center
Responsible party: Sponsor
First posted: Aug 11, 2022
Start date: Apr 21, 2021
Primary completion: Jul 1, 2027 (estimated)
Completion: Jul 1, 2027 (estimated)
Last update: May 22, 2026

Study contacts

Chenyang Wang, MD

principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hematologic Neoplasms→

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion